The Pfizer Inoculations Do More Harm Than Good

THE PFIZER INOCULATIONS FOR COVID-19
MORE HARM
THAN GOOD
Contact us
[email protected]
www.canadiancovidcarealliance.org
P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D
WHO WE ARE
Our alliance of over 500 independent Canadian

doctors, scientists, and health care practitioners is
committed to providing quality, balanced, evidence-based
information to the Canadian public about COVID-19 so that
hospitalizations can be reduced, lives saved, and our
country safely restored to normal as quickly as possible.
2
WE SUPPORT
The doctor/patient
relationship and personalized
care
Informed consent and
treatment options
Free and open scientific
discourse
Safe & effective vaccines
3
FIRST, DO NO HARM
The federal, provincial and municipal governments in Canada have a

responsibility to protect the health of Canadians as well as our
Charter Rights and Freedoms. Any medical interventions
approved by Health Canada must first be PROVEN SAFE.
Due diligence in research, as well as adherence to established

protocols of the doctor/patient relationship, informed consent
and scientific inquiry are essential to carrying out that responsibility.
Deviating from those practices, causing harm and failing to

disclose risks of harm is negligent at best.
4
OVERVIEW
Hierarchy of evidence • Failure to test - Why it matters • This is supposed to be rare - VIDEO of athletes
Pfizer’s 2 month data report, Dec 31 2020 • 12 - 15 trial - All risk, no benefit collapsing
• ARR vs RRR explained - VIDEO • 12 - 15 trial - Failure to report serious adverse • Pfizer’s post marketing pharmacovigilance
• Early unblinding of Pfizer’s randomized control events report
trial • 5 - 11 year olds - Risking their health Considerable evidence of conflict of interest
Pfizer’s 6 month data report, Sep 15 2021 • Myocarditis is serious • Pfizer is making billions
• Increased risk of illness • The FDA abandons “First, do no harm” • The public record of Pfizer’s corporate culture
• Increased risk of death • 5 - 11 year olds - No informed consent • Links to articles on Pfizer’s past behaviour
The Pfizer Trials - What went wrong • The BMJ Pfizer trial whistleblower article • Conflicts of interest among Pfizer report authors
• Pfizer did not follow established protocols A critical eye on the Sep 15 2020 report • The CDC has redefined “vaccine”
• Misleading demographics - Wrong age • 6 month data manipulation - Mixed cohorts • The media has been captured - VIDEO
• Misleading demographics - Tested on healthy, • The Pfizer trials did not prove safety - they This is no way to manage a supplier
given to sick proved harm The inoculations should be withdrawn
• Inadequate control groups How this is playing out in the real world immediately
• Did not track biomarkers • Roll out surveillance - You don’t find what you Recommended reading & viewing
• Wrong clinical endpoints don’t look for
• Not tested for spread reduction • Rising incidents of heart issues in young people
• Subjective testing (Ontario Public Health Report)
• Missing data - Lost to follow up and Suspected, • This is not normal - High incidences of deaths in
but unconfirmed athletes (German, Israeli news articles)
5
THE HIERARCHY OF EVIDENCE

Levels of Scientific Evidence
• A randomized control trial is LEVEL 1

Evidence, the highest form of evidence there is. It is
considered the Gold Standard and is the only way
to prove something is true.
• Models are LEVEL 5 or lower as they are

expert opinion/speculation.
•Policy should be determined by the highest

level of evidence available, LEVEL 1.
6
PFIZER’S ORIGINAL TRIAL REPORT

DECEMBER 31 2020
• Published in New England Journal of Medicine

• Showed 2 months worth of safety & efficacy data
• Described starting with 43,548 people divided into:
1. Treatment group (received inoculation)
2. Control group (received saline)
for 2 months to see who developed COVID-19
• The claim was that the inoculations were safe and showed 95% efficacy
7 days after the 2nd dose. But that 95% was actually Relative Risk
Reduction. Absolute Risk Reduction was only 0.84%.
7
ABSOLUTE RISK REDUCTION

VS RELATIVE RISK REDUCTION
https://rumble.com/vobcg5-relative-vs-absolute-risk-reduction.html
8
EARLY UNBLINDING OF RANDOMIZED CONTROL TRIAL

= NO LONG TERM SAFETY DATA
WHAT WAS SUPPOSED TO HAPPEN WHAT ACTUALLY HAPPENED

INOCULATED PLACEBO
INOCULATED PLACEBO
GROUP GROUP
GROUP GROUP
●●●●●●●●● ●●●●●●●●● July 27 2020
●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● July 27 2020
●●●●●●●●● ●●●●●●●●● Phase III Begins ●●●●●●●●● ●●●●●●●●●
●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● Phase III Begins
●●●●●●●●● ●●●●●●●●● The participants are evenly divided into ●●●●●●●●● ●●●●●●●●●
●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● The participants are evenly divided into Inoculated and Placebo
2020 ●●●●●●●●● ●●●●●●●●● Inoculated and Placebo groups of about ●●●●●●●●● ●●●●●●●●●
●●●●●●●●● ●●●●●●●●● 2020 ●●●●●●●●● ●●●●●●●●● groups of about 21,000 each. The study is blind.
●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
●●●●●●●●● ●●●●●●●●● 21,000 each. The study is blind, so ●●●●●●●●● ●●●●●●●●●
●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
●●●●●●●●● ●●●●●●●●● participants don’t know which group they ●●●●●●●●● ●●●●●●●●●
●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● Dec 31 2020
●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
●●●●●●●●● ●●●●●●●●● are in. ●●●●●●●●● ●●●●●●●●● Release 2 month data report. The trial is unblinded early.
●●●●●●●●● ●●●●●●●●●
●●●●●●●●●●●●●●●●●● Crossover Occurs
●●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●● The participants from the Placebo Group are given the
●●●●●●●●●●●●●●●●●●
2021 ●●●●●●●●●●●●●●●●●● NO opportunity to take the inoculation and by early 2021, the
2021 ●●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●●
↓ ↓ ●●●●●●●●●●●●●●●●●● majority of them have crossed over to the inoculated group. It’s
●●●●●●●●●●●●●●●●●● DATA
●●●●●●●●●●●●●●●●●● no longer a randomized control trial, as control group
●●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●● is gone.
2022 NO
↓ ↓ 2022
↓↓ DATA
May 2 2023
End of Phase III Clinical Trial May 2 2023
2023 This is the point where the trial can be NO End of Phase III Clinical Trial
↓ ↓ unblinded and the Placebo group 2023 The long term safety data that was supposed to be assessed
offered the intervention if it’s indicated ↓↓ DATA at this point is no longer possible to ascertain as the
and they consent. placebo group crossed over two years previously.
9
The n e w e ng l a n d j o u r na l of m e dic i n e
PFIZER’S 6 MONTH REPORT DATA
Original Article
LEVEL 1 EVIDENCE OF HARM Safety and Efficacy of the BNT162b2 mRNA

Covid-19 Vaccine through 6 Months
S.J. Thomas, E.D. Moreira, Jr., N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart,
J.L. Perez, G. Pérez Marc, F.P. Polack, C. Zerbini, R. Bailey, K.A. Swanson,
X. Xu, S. Roychoudhury, K. Koury, S. Bouguermouh, W.V. Kalina, D. Cooper,
R.W. Frenck, Jr., L.L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, Q. Yang,
P. Liberator, D.B. Tresnan, S. Mather, P.R. Dormitzer, U. Şahin, W.C. Gruber,
• Pfizer’s most recent report indicates an Efficacy of 91.3%. and K.U. Jansen, for the C4591001 Clinical Trial Group*
(Which means a reduction in positive cases compared to A BS T R AC T
BACKGROUND
BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine The authors’ full names, academic de-
placebo group.) encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syn- grees, and affiliations are listed in the
Appendix. Dr. Dormitzer can be contact-
drome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly ed at [email protected] or at
efficacious against coronavirus disease 2019 (Covid-19) and is currently approved, Pfizer, 401 N. Middletown Rd., Pearl River,
conditionally approved, or authorized for emergency use worldwide. At the time of NY 10965.
initial authorization, data beyond 2 months after vaccination were unavailable. *A list of the investigators in the C4591001
Clinical Trial Group is provided in the
METHODS Supplementary Appendix, available at
NEJM.org.
• But it also showed, compared to the placebo group, an In an ongoing, placebo-controlled, observer-blinded, multinational, pivotal efficacy
trial, we randomly assigned 44,165 participants 16 years of age or older and 2264 This article was published on September 15,
2021, at NEJM.org.
participants 12 to 15 years of age to receive two 30-µg doses, at 21 days apart, of
increase in illness and deaths. BNT162b2 or placebo. The trial end points were vaccine efficacy against laboratory- N Engl J Med 2021;385:1761-73.
DOI: 10.1056/NEJMoa2110345
confirmed Covid-19 and safety, which were both evaluated through 6 months after Copyright © 2021 Massachusetts Medical Society.
vaccination.
CME
RESULTS at NEJM.org
BNT162b2 continued to be safe and have an acceptable adverse-event profile. Few
participants had adverse events leading to withdrawal from the trial. Vaccine ef-
• There is no benefit to a reduction in cases if it comes at ficacy against Covid-19 was 91.3% (95% confidence interval [CI], 89.0 to 93.2)
through 6 months of follow-up among the participants without evidence of previ-
ous SARS-CoV-2 infection who could be evaluated. There was a gradual decline in
the cost of increased sickness and death. vaccine efficacy. Vaccine efficacy of 86 to 100% was seen across countries and in
populations with diverse ages, sexes, race or ethnic groups, and risk factors for
Covid-19 among participants without evidence of previous infection with SARS-
CoV-2. Vaccine efficacy against severe disease was 96.7% (95% CI, 80.3 to 99.9). In
South Africa, where the SARS-CoV-2 variant of concern B.1.351 (or beta) was pre-
dominant, a vaccine efficacy of 100% (95% CI, 53.5 to 100) was observed.
CONCLUSIONS
Through 6 months of follow-up and despite a gradual decline in vaccine efficacy,
BNT162b2 had a favorable safety profile and was highly efficacious in preventing
Covid-19. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.)
n engl j med 385;19 nejm.org November 4, 2021 1761

The New England Journal of Medicine
Downloaded from nejm.org on November 10, 2021. For personal use only. No other uses without permission.
Copyright © 2021 Massachusetts Medical Society. All rights reserved.
10
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2110345?articleTools=true
A significant increase in illness, which the Pfizer

INCREASED RISK OF inoculations were supposed to reduce.
ILLNESS
Screen capture from Pfizer 6 Month Supplementary Appendix

BNT162b2 Placebo Risk Change
Efficacy
(Meaning number of people 77 850 -91%
diagnosed with COVID-19.)
Related Adverse Event

(Meaning an investigator has assessed it as 5,241 1,311 +300%
related to the BNT162b2 injection.)
Any Severe Adverse Event

(Interferes significantly with normal function.)
262 150 +75%
Any Serious Adverse Event

(Involves visit to ER or hospitalization.)
127 116 +10%
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months - Supplementary Appendix
11
INCREASED RISK OF
DEATH BNT162b2 Placebo
Screen capture from Pfizer 6 Month Supplementary Appendix
Deaths before unblinding 15 14
(In Table S4 of Supplementary Appendix)
Deaths after unblinding 5

(Not in table, but mentioned in text of 6 month report. See quote below.)
Total Deaths 20 14
“After unblinding” means when the Placebo participants were given the opportunity to “cross
over” and take the BNT162b2 inoculation.*
“…3 participants in the BNT162b2 group and 2 in the original placebo group
who received BNT162b2 after unblinding died.”
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Concerning Causes of Death

BNT162b2 Placebo
Total COVID-19 Related Deaths 1 2

Deaths Related to Cardiovascular Events 9 5
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months - Supplementary Appendix
12
*A total of 19,525 subjects originally randomized to placebo received at least one dose of BNT162b2 after unblinding (Dose 3 and Dose 4) and before the March 13, 2021 data cutoff.
THE PFIZER TRIALS
WHAT WENT WRONG
13
Regarding the persistent claim that the COVID-19 inoculation
products do not need to be tested, because mRNA technology has
PFIZER DID NOT FOLLOW already undergone testing: mRNA technology is the delivery
mechanism, not the inoculation. That’s like saying that since we’ve
used syringes safely before, anything injected via syringe is safe.
ESTABLISHED PROTOCOLS (And in fact, there are still a lot of unknowns about the effects of the
mRNA delivery mechanism.)
NORMALLY, VACCINE DEVELOPMENT LOOKS LIKE THIS, WITH A TIMELINE OF 5 TO 10 YEARS.
1 2 3 4 5 6 7 8 9 10
In Vitro & Human Trials PHASE I Human Trials PHASE II Human Trials PHASE III
Animal Models Safety, dosing, immune responses Safety & immune responses Safety & efficacy
RARELY, IT CAN BE DONE IN AS LITTLE AS 5 YEARS.
1 2 3 4 5
In Vitro & Human Trials Human Trials Human Trials
Animal PHASE I PHASE II PHASE III

Models
FOR THE COVID-19 INOCULATIONS, IT WAS DONE IN 1 YEAR.
2020 2021
PHASE III • Animal testing • Phases II/III • After 2 months • The trials were • Phase III trials
continues,
but was skipped were of Phase II/III, unblinded are ongoing
unblinded
combined Emergency until 2023
Use
Authorized
ROLLOUT BEGINS
14
MISLEADING DEMOGRAPHICS
WRONG AGE FOR TARGET POPULATION
When designing a trial for the efficacy and safety of a potential treatment, the focus should be on the target population who could most benefit from that treatment. Instead
Pfizer chose participants from younger demographic that would be a) less likely to need a vaccine, b) less likely to suffer an adverse event during a trial, c) more likely to respond well to a
vaccine, as the elderly have comparatively poor immune responses.
Actual Risk of Death by Age from COVID-19 Pfizer Trial Demographics
85% of the people

most at risk from
COVID-19 are over 75.
Yet 75+ year olds

represent only 4% of
trial subjects.
COVID-19 Deaths per capita by age in the United States (as of Jun 5, 2021). Population-based on U.S. CDC WONDER FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING VACCINE (VACCINATION PROVIDERS)
Bridge-Race Population Estimate 2019. Data obtained from https://wonder.cdc.gov/bridged-race-v2019.html EMERGENCY USE AUTHORIZATION (EUA) OF THE PFIZER-BIONTECH COVID-19 VACCINE TO PREVENT
CORONAVIRUS DISEASE 2019 (COVID-19)
https://labeling.pfizer.com/ShowLabeling.aspx?id=14471
15
MISLEADING DEMOGRAPHICS
TESTED ON HEALTHY, GIVEN TO SICK
Pfizer Trial Protocols - Exclusions
REAL WORLD PFIZER TRIAL

CO-MORBIDITIES CO-CONDITIONS IMPLICATIONS FOR ROLL OUT
• We are told the inoculations are “safe.” Yet many health conditions
95% of people Only 21% had a - in fact a list several pages long - were excluded from the trials,
including pregnant or breastfeeding women, people with allergies, with
who have died with co-existing psychiatric conditions, immunocompromised people, people with
COVID-19 have had at condition. bleeding disorders, people who had previously tested positive for
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2034577?
articleTools=true COVID-19, people who had been prescribed steroids, etc., so there has
least 1 co-morbidity
never been any data to make safety claims about those people. Yet they
listed as cause of death. are also not excluded from mandates and vaccine passports.
The average is 4 co- • The vaccines were tested on the healthy, and then immediately
morbidities. given to the frailest members of the society - the elderly with
https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm?
fbclid=IwAR3- multiple health conditions. This is unscientific and unethical.
wrg3tTKK5-9tOHPGAHWFVO3DfslkJ0KsDEPQpWmPbKtp6EsoVV2Qs1
Q#Comorbidities
16
Experimental Group Placebo Group

INADEQUATE
CONTROL GROUPS
UNEXPOSED UNEXPOSED
+ +
Pfizer only observed 2 groups:
• UNEXPOSED & INOCULATED INOCULATED NOT INOCULATED
• UNEXPOSED & NOT INOCULATED
They should have included two more
groups: Should also have included
• EXPOSED & INOCULATED, people
who had recovered, then got the
inoculation, to see if the inoculation
was safe for them EXPOSED EXPOSED
• EXPOSED & NOT INOCULATED + +
people who were recovered and not
INOCULATED NOT INOCULATED
inoculated to see how the inoculations
stacked up against natural immunity
17
LOW QUALITY SAFETY SCIENCE

DIDN’T TRACK BIOMARKERS
As Kostoff et al. highlighted in a recent paper, “Why are we vaccinating children against COVID-19?”
(highly recommended), that while the Pfizer trials tested for antibodies and tracked adverse events in terms
of symptoms, they didn’t test for adverse events at the subclinical (pre-symptom) level.
This was extremely unsafe, because symptoms/diseases are typically end points of processes Micro-clots resulting
that can take months, years, or decades to surface. By the time you get to symptoms, things can have gone
pretty wrong. (Think diabetes or high blood pressure, where the disease can be quite advanced before any from the inoculation that
symptoms occur.) Pfizer should have been tracking biomarkers that would have been early
warning indicators for disease caused by the inoculations.
were insufficient to cause
High quality safety science would have meant they should have tested before & after
observable symptoms
inoculation for:
• d-dimers for evidence of enhanced coagulation/clotting (several of our doctors have noticed
could raise the
increased levels of d-dimers in inoculated patients presenting with stroke like symptoms - video available baseline for
here)
• C-reactive protein for evidence of enhanced inflammation thrombotic disease.
• troponins for evidence of cardiac damage
• occludin and claudin for evidence of enhanced barrier permeability
• blood oxygen levels for evidence of enhanced hypoxia
• amyloid-beta and phosphorylated tau for evidence of increased predisposition to Alzheimer’s
disease
• Serum HMGB1, CXCL13, Dickkopf-1 for evidence of an increased disposition to autoimmune RONALD N. KOSTOFF A, *, DANIELA CALINA B, DARJA KANDUC C, MICHAEL B.
BRIGGS D, PANAYIOTIS VLACHOYIANNOPOULOS E, ANDREY A. SVISTUNOV F,
disease, etc. ARISTIDIS TSATSAKIS
“WHY ARE WE VACCINATING CHILDREN AGAINST COVID-19?”
18
The Pfizer trial measured:
1. Adverse events/symptoms
2. SARS-CoV-2 serum neutralizing antibody levels
WRONG CLINICAL ENDPOINTS 3. SARS-CoV-2 anti-S1 binding antibody levels & anti- RBD binding antibody levels
4. Effectiveness (whether or not people contracted COVID-19, which was decided with
SHOULD HAVE FOCUSED ON ALL CAUSE MORTALITY & ILLNESS a PCR test + 2 symptoms)
The fear with COVID-19, was that it was going to a) kill people, WHAT SHOULD HAVE HAPPENED
b) make them sick. (After the proper early safety phases of development were completed.)
So any COVID-19 vaccine clinical trial should set out to ask the question “Do “Do people who take the vaccines have less
people who take the vaccines have less illness and death than those illness and death than those who don’t?”
who don’t?”
YES. Proceed to long NO. Go back to the
Illness + Death should be the CLINICAL ENDPOINTS. And not just illness + terms safety studies. drawing board.
death with COVID-19, but any and all illness and death, in order to make
sure that the vaccines are not causing harm.
This is well known. It was learned decades ago with cancer drug trials. At WHAT ACTUALLY HAPPENED
(Without the proper early safety phases of development having been completed.)
first, they used a clinical endpoint of “Did the drug shrink the cancer?” If it did,
they called it effective. But it turned out the drugs were not only killing “Do people who take the vaccines test positive
cancer, they were killing patients. They were forced to change the design of for COVID-19 less often?”
their trials and switch to “all cause mortality” as the primary endpoint instead
and show that people receiving the drug actually live longer than those who
YES. Proceed to world NO. (The trial set up
don’t. (J.Bart Classen has written an excellent research article on the subject.
wide roll out. made this result unlikely).
Read here.)
19
NOT TESTED FOR SPREAD REDUCTION

VACCINE PASSPORTS UNJUSTIFIED
Although vaccine passports are now being used to ostensibly prevent

or reduce transmission of COVID-19, this outcome was never studied
in the trial and it is inappropriate to assign that capability to these
inoculations. There is no evidence at all that they reduce the
spread of disease and transmission was never one of the
study’s endpoints.
20
TESTING FAILURES
SUBJECTIVE TESTING
The Pfizer trials DID NOT test all participants for
COVID-19. Instead, they instructed their investigators to test
only those with a COVID-19 symptom and left it up to their
discretion to decide what those were.
This means that:
✦ Asymptomatic infection would be missed

entirely
✦ A high level of subjectivity was introduced to the

study - an investigator had the ability to sway
the results
All participants should have been tested.
✦ The lack of objective systematic testing makes results
unreliable
21
Confirmed Cases
P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D Dec 31 2020 Report
MISSING DATA
✦ LOST TO FOLLOW UP
✦ SUSPECTED, BUT UNCONFIRMED Lost to Follow Up
Dec 31 2020 Report
INOCULATED PLACEBO
GROUP GROUP
ENDPOINT DATA - Confirmed COVID Cases 8 162

Participants Lost to Follow Up 80 86
Suspected, but Unconfirmed Cases 1,594 1,816
The basis for the Emergency Use Authorization was the Confirmed COVID cases of 8 vs 162, which meant a
Relative Risk Reduction of 95%. But when dealing with such a small number of cases, any change can
impact the results significantly.
Lost to follow up means they lost touch with those subjects and can’t confirm whether they got sick or not.
They don’t know.
Suspected, but unconfirmed means these people were symptomatic for COVID-19, but were never
tested. (Discretion for testing was left up to the investigator.) Suspected but Unconfirmed
Vaccines and Related Biological Products Advisory Committee Meeting December 10, 2020
The fact that the Lost to Follow Up and Suspected but Unconfirmed numbers are higher - and here they are even FDA Briefing Document Pfizer-BioNTech COVID-19 Vaccine
significantly higher - than the End Point numbers means that this data is unreliable. The study should not
have been accepted in this state. In normal scientific practice they should have returned to investigate further.
22
FAILURE TO TEST If you add the Suspected to the

Confirmed Cases, the Relative
WHY IT MATTERS Risk Reduction changes to
19%. Less than 50% is
ineligible for EUA.
20%
The very high proportion of
Suspected, but
Unconfirmed participants. RRR
16%
They had symptoms, but were 19%
never tested.
12% 1,978
1,816
1,594 1,602
8%
RRR
Proportion of Participants
95%
4%
162 + =
8
0%
Inoculation Placebo Inoculation Placebo Inoculation Placebo
No. of Confirmed
CONFIRMED Cases
CASES SUSPECTED, but not
Suspected, NOT Confirmed
CONFIRMED CONFIRMED
Confirmed + +Suspected
SUSPECTED
23 Symptoms + PCR test Symptoms, but no PCR test Symptoms, w and w/o PCT test
12-15 ADOLESCENT TRIAL

ALL RISK, NO BENEFIT
• This study was severely underpowered, as a study this small will not
show up risk.
- Inoculated group - 1,005 (0 tested positive for COVID-19)
- Placebo group - 978 (18 tested positive for COVID-19)
• Pfizer claimed these were great results, but since adolescents are at
statistically 0% risk of death from COVID-19, and very low risk of severe
illness, the inoculation is of little benefit to them. Instead, it
presents a very real risk of adverse events.
• But the adolescent Pfizer study wasn’t actually designed to find those. A
serious adverse event, including death, that occurred at a 1/800
rate might not even show up in a sample of 1,005 people.
• But in this case, it did. Among the 1,005 adolescents, there WAS
at least one serious adverse event - Maddie de Garay.
“For children without a serious medical condition, the danger
of severe Covid is so low as to be difficult to quantify.”
24 -COVID AND AGE, Oct 12, 2021, New York Times
12 -15 ADOLESCENT TRIAL

FAILURE TO REPORT
SERIOUS ADVERSE EVENTS
Maddie de Garay is a 12 year old trial participant
who developed a serious reaction after her second
dose and was hospitalized within 24 hours.
Maddie developed gastroparesis, nausea and

vomiting, erratic blood pressure, memory loss, brain
fog, headaches, dizziness, fainting, seizures, verbal
and motor tics, menstrual cycle issues, lost feeling from
the waist down, lost bowel and bladder control and
had an nasogastric tube placed because she lost her
ability to eat. She has been hospitalized many times,
and for the past 10 months she has been
wheelchair bound and fed via tube.
In their report to the FDA, Pfizer described her

injuries as “functional abdominal pain.”
Emergency Use Authorization Amendment
25
FDA BRIEFING DOCUMENT
EUA AMENDMENT REQUEST FOR PFIZER-BIONTECH COVID-19 VACCINE
FOR USE IN CHILDREN 5 THROUGH 11 YEARS OF AGE
5 - 11 YEAR OLDS
RISKING THEIR HEALTH
Re: the 5 to 11 year old cohort
In this table, Pfizer, using predictive modelling

acknowledges that their inoculations WILL
cause myocarditis, but optimistically claims there
will be zero deaths from myocarditis in any of their
modelled (speculation, level 5 evidence) scenarios.
But even if it were true, there is no justification

for causing harm to children this way. FIRST, DO
NO HARM.
There is now such a high expectation of heart

problems from the inoculations among children that
Sick Kids is putting out brochures on how
to deal with them.
Low Level (Level 5 Evidence)

SPECULATION - A Predictive Model
26
MYOCARDITIS
IS SERIOUS
MYOCARDITIS
“Myocarditis is an inflammatory process of the myocardium.
(Heart muscle.) Severe myocarditis weakens your heart so
that the rest of your body doesn't get enough blood. Clots can
form in your heart, leading to a stroke or heart attack.”
THE US NATIONAL CENTRE FOR BIOTECHNOLOGY INFORMATION
“The mortality rate is up to 20% at 6.5 years.”

https://jcmr-online.biomedcentral.com/articles/10.1186/1532-429X-13-S1-M7
27
THE FDA ABANDONS

FIRST, DO NO HARM
Medical interventions are supposed to be PROVEN SAFE BEFORE

the are rolled out in the population.
Yet Dr. Eric Rubin, one of the 18 members of the FDA advisory
panel who voted, to approve the inoculations for children 5 - 11,
actually said the opposite, and suggested that a population level
roll out was an appropriate way to test for adverse
events.
It’s worth noting that Dr. Eric Rubin is the editor-in-chief of the
“We’re never going to learn about how safe this vaccine is unless we start
New England Journal of Medicine, which publishes the giving it. That’s just the way it goes. That’s how we found out about rare
Pfizer trial reports. complications of other vaccines like the rotavirus vaccine. And I do think we
should vote to approve it.”
Dr. Eric Rubin, FDA advisory panel member,

Harvard professor & editor-in-chief of the New England Journal of Medicine
28 Vaccines and Related Biological Products Advisory Committee – 10/26/2021
5 - 11 YEAR OLDS
NO INFORMED CONSENT
• Direct-to-consumer advertising of prescription drugs is illegal in

Canada, yet politicians from all levels of government are marketing
inoculations to children, using cartoons and mascots.
• They are proclaiming the inoculations to be safe, yet the data is not
there to back that up. In addition to admitting that their inoculations can
cause myocarditis, Pfizer also admits, right in their report, that their long
term immune response, efficacy & safety data is limited and
that their studies weren’t powered to find “rare” side effects as
only1,517 kids got the inoculation.
• How many parents would take their kids to get this shot if they were
informed of this? The law of informed consent says they should
be, but it’s not happening.
https://www.nejm.org/doi/full/10.1056/NEJMoa2116298
29
THE BRITISH MEDICAL JOURNAL

PUBLISHES WHISTLEBLOWER STORY
On November 2nd, the British Medical Journal released an article about their
investigation into Ventavia, one of the research companies Pfizer hired to
FEATURE
conduct the trials.
It’s quite damning. The whistleblower is a Regional Director who

ION egrity issues in
BMJ INVESTIGAT
BMJ: first pub
Madrid, Spain
2021;375:n2635
actually reported her company to the FDA for: Cite this as: BMJ
istle on data int
5 her blows the wh
0.1136/bmj.n263
http://dx.doi.org/1 Covid-19: Researc
mber 2021
Published: 2 Nove
• Falsifying data er’s pivotal
trial to carry out Pfiz
Pfizer’s vaccine company helping l D Thacker
a contract research ory oversight. Pau
lished as 10.1
• Unblinding participants r practices at grity and regulat

Revelations of poo raise questions about data inte
trial
• Not following up and testing participants who reported covid-19 vaccine
reports ng the
st Jackson for taki
stigative journali later questioned
symptoms Paul D Thacker inve e, executives
chief executiv
n and tos.
136/bmj.n2635
Pfizer’s chairma billions pho have occurred

In autumn 2020 n letter to the unblinding may
released an ope g their Early and inadvertent ording to the trial’s design,
• Mislabelling specimens Albert Bourla, were investin er scale. Acc and
nd the world who 9 vaccine to end on a far wid ons ible for preparing
of people arou e cov id-1 e resp
and effectiv rating unblinded staff wer s vaccine or a
hopes in a safe re, we are ope y drug (Pfizer’
pan dem ic. “As I’ve said befo te, exp lain ing to administering the stud e to pres erve the blinding
the rla wro was to be don uding
on 2 Novemb
science,” Bou ine placebo). This r site staff, incl

Several other employees backed up her account. Despite all this, at the speed of ect a Pfizer vacc ants and all othe
the public whe
n they could exp es.1
Stat of trial particip , at Ventavia,
ator. However ent
ed in the United cipal investig
to be authoris Pfiz er’s vacc ine the prin BMJ that drug assignm ants’
The icip
er 2021.
neither Pfizer, nor the FDA ever audited or investigated the research ing Jackson told g left in part
But, for research
ers who were test autumn, speed
ing that touts were bein
s in Texas dur confirmation prin onnel. As a
at several site y and to blinded pers two months
e at the cost of data integrit loye d cha rts, accessible in Sep tem ber,
company, Pfizer never disclosed the problems in its EUA application, and in fact, may have com n
A regional dire
ctor who was emp up corrective action take
Gro nd 1000
patient safety. tavia Research ent and with arou e
into trial recruitm enrolled, quality assuranc
Downloaded
organisation Ven y falsified data,

Pfizer has now hired that same Researcher, Ventavia, to run four more at the research ants already for staff to
that the compan ed particip e upd ated with instructions
has told The BMJ , employed inadequately train checklists wer
ed pati ents up on adv erse assi gnm ents from charts.
unb lind w drug
COVID-19 clinical trials. 020
vaccinators, and
was slow to follo se III trial. Staff remove
tal pha late September2
in Pfizer’s pivo of a meeting in s a Ventavia
events reported checks were In a recording
quality control were and two director company
who conducted of problems they between Jackson rd exp laining that the
by the volu me be hea of errors
overwhelmed a of these executive can s and number
from http://www.
fying Ventavi quantify the type

repeatedly noti , wasn’t able to trial
30 finding. After , Brook Jackson n examining the
lem s, the regional director and Dru g they wer e finding whe . “In my mind, it’s
prob Foo d quality con trol
plaint to the US r the paperwork for utive says.
emailed a com a fired her late ,” a Ventavia exec
(FDA). Ventavi ens something new every day nt.”
Administration The BMJ with doz it’s significa
same day. Jack
son has provided photos, audio
nts, “We know that data entry queries,
ume
bmj.com/ on 3
pan y doc up with

of internal com not keeping arch
emails. Ventavia was the contract rese .
recordings, and il sent by ICON,
Nov
shows an ema nered on the trial

which Pfizer part email:
y management organisation with tavia in a September 2020
Poor laborator the larg est inde d Ven que ries are
Ven tavi a calls itself Tex as ICON rem this study is that all r
On its web site y in tion for ted ove
arch compan “The expecta highligh
ed clinical rese tract 24hrs.” ICON then
privately own won for its con ressed within three days in
y awards it has the add ries older than ch
and lists man has told The BMJ that, during 100 outstanding que d two indi viduals for whi
2 son
ember 2021 by
work. But Jack at Ventavia in es include

was employed yellow. Exampl
two weeks she ly informed her “Subject has repo
rted with Severe subjects
ocol,
, she repeated ent ons … Per prot
September 2020 agement, pati symptoms/reacti 3 local reactions should be
sup erio rs of poo r laboratory man issues. Jackson g Gra de NED
s, and data integrity ly experiencin firm if an UNPLAN
safety con cern ious se con nding
itor who prev contacted. Plea ate the correspo
clinical trial aud e to made and upd
guest. Protect
was a trained position and cam CONTACT was trial protocol

of operations According to the “to
held a director 15 yea rs’ experience in form as appropriate.” hav e occu rred
more than t. should
Ventavia with and managemen phone contact e whether a
coordination the a tele ils and determin
clinical research not dealing with rtain further deta cated.”
Ventavia was late asce ically indi
Exasperated that documented several matters
son One site visit is clin
s, Jack pho ne.
ed by copyrig
problem her mobile FDA inspection

ng photos on g on
ht.
one night, taki wed needles Worries over

to The BMJ, sho a w that problem
s had been goin ng
photo, provided tic biohazard bag instead of Documents sho ulated amo
plas ion items” circ
discarded in a ther sho wed vaccine for wee ks. In a list of “act ust 2020 , sho rtly after
er box. Ano early Aug
sharps contain participants’ tavia leaders in g, a Ventavia
erials with trial in the Ven re Jackson’s hirin with
packaging mat on them left out began and befo staff members
numbers written a the trial tified three site
identification icipants. Ventavi executive iden
ntia lly unblinding part
open, pote 1
| doi: 10.1136/bmj.n2635
2021;375:n2635
the bmj | BMJ
The new e
ng l a nd jo
u r na l of m e di c
ine
Or igin
al Arti
cle
Safety an
d Effi
Covid-19 cacy of the BN
S.J. Thom
Vaccine T16
as, E.D. through 2b2 mRNA
J.L. Perez Moreira,
Jr., 6 Month
X. Xu, S. , G. Pérez Marc, N. Kitchin, J. Ab
Roych F.P. Po salon
s
R.W. Fre oudhury , A. Gurtm
nck, , K. Koury lack, C. Zerbini,
P. Libera Jr., L.L. Hamm , S. Boug R. Bailey an, S. Lockhart,
, K.A. Sw
tor, D.B itt, Ö. Tü uermou an
. Tresnan reci, H. h, W.V.
and K.U , S. Nell, Kalina, D. son,
Cooper,
. Jansen Mather, P.R. Do A. Schaefer, S.
, for the rmitzer, Ünal, Q.
C4591001 U. Şahin Yang,
Clinical , W.
Trial Grou C. Gruber,
p*
A BS T R
BACKGRO AC T
UND
BNT162b
2
encoding is a lipid nano
a particle–
for
drome cor prefusion-stabi
onavirus lized, me mulated, nucle
eff icacio mbrane-a osi
us agains 2 (SARS-CoV-2) nchored de-modif ied RN
condit ion t cor ful severe acu A
ally approv onavirus diseas l-length spike pro te respir vaccine The aut
initial aut tein. BN atory syn gre hors’ full
horization
ed, or aut
horized
e 2019 (Co
vid-19) an T162b - es, and names,
aca
, dat a bey for d is curren 2 is highly Appendix. Dr.affiliations are listedemic de-
ME THOD
S
ond 2 mo emergency use
worldwid tly approv ed Dormit d in the
A CRITICAL EYE BACK ON In an on
go
nths aft
er vaccin
ation we
e. At the
re unava
ed, Pfizat philip.dormitze zer can be contact
time of NY 109 er, 401 N.
65.
Middlet
[email protected]
own Rd. om or at
-
trial, we ing, placebo-con , Pearl Rive
randoml trolled, ob ilable. r,
participa y assign ser ver -bl *A list of
the
nts 12 to ed 44,16 Clinical investig
ators in
BNT162b 15 years 5 participa inded, multinati
on Trial Gro the C45910
2 of age to nts al, pivota Sup up is pro 01
confirme or placebo. The receive tw 16 years of age l eff icacy NEJ plementary Append vided in
d tria o 30-µg or M.org. ix, availab the
vaccinati Covid-19 and saf l end points we doses, at older and 2264 This le at
on. ety, which re vac 21 arti
were both cine eff icacy aga days apart, of 2021, at cle was published on
NEJM.o
RESULT S evaluated inst labora rg. September
15,
through tor y- N Eng
BNT162b 6 month l J Med 202
2 s after DOI: 10.1 1;385:17
61-7
participa continued to be 056/NE
nts saf Copyright JMoa21103 3.
© 2021 45
THE SEP 15 2021 REPORT ficacy aga had adverse eve e and have an
through
6
inst Covid
-19 was
nts leadin
g to wit
accept abl
hd
e advers
e-event pro CM E
Massach
usetts Med
ical Socie
ty.
ous SARS months of follow 91.3% (95% con rawal from the file. Few at NEJM.org
-CoV-2 inf -up amon fidence trial. Vac
vaccine ect g int erv al [CI cin e ef-
eff ion wh the partic
populat ion icacy. Vaccine eff o could be evalua ipants without ], 89.0 to 93.2)
ica ted. There evidence
Covid-19 s with diverse age cy of 86 to 100 was a gra of previ-
am %
CoV-2. Vac ong participants s, sexes, race or was seen across dual decline in
cine eff ica without eth cou
South Afr cy agains evidence nic groups, and ntries and in
ica risk factor
dominant, , where the SA t severe disease of previous inf
RS wa ection wit s for
a vaccin h SA
e eff icacy -CoV-2 variant of s 96.7% (95% CI,
CONCLUS of 100% concern 80.3 to 99. RS-
IONS (95% CI, B.1 9). In
Through 53.5 to 100 .351 (or bet a) wa
6 month ) wa s obser ved s pre -
BNT162b s of follow .
2 -up and
Covid-19 had a favorable despite a
. (Funded safety pro gradual
by BioNT file and decline
ech and in
Pfizer; Cli was highly eff ica vaccine eff ica
nicalTria cious in cy,
ls.gov nu preventin
mber, NC g
T0436872
8.)
n engl
j med 385
;19 nejm.org
Downlo Nov
aded from The New ember 4,
nejm.org England 2021
on Novemb Journal
Copyrig er 10, 202
ht © 202 1. For per of Medicine
1 Massac
husetts Me sonal use only.
dical Soc No other 1761
iety. All use
rights rese s without permis
rved. sion.
31 RUNNING FOOTER ELEMENT

The new e
ng l a nd jo
u r na l of m e dic
ine
P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D Origin
al Articl
e
Safety an
d Eff
Covid-19 icacy of the BN
S.J. Thom
Vaccine T1
as, through 62b2 mRNA
J.L. Pere E.D. Moreira, Jr.,
z, G. Pére N. Kitch
6 Month
X. Xu, S. z in, J. Absa s
R.W. Fren Roychoud Marc, F.P. Pola lon,
ck, C. Zerb A. Gurt
ck, hury, K.
Koury, S. ini, R. Baile man, S. Lockhart
P. Liberator Jr., L.L. Hammitt Bouguer
, D.B. Tres , Ö. Türe mouh, W.V y, K.A. Swanson ,
ci, . Kalina, ,
and K.U. nan, S. Mather, H. Nell, A. Scha D.
Jansen, P.R. efer, S. Üna Cooper,
for the C459 Dormitzer, l, Q. Yang
1001 Clini U. Şahin, ,
6 MONTH DATA MANIPULATION BACKGRO
A BS T R
AC T
cal Trial W.C.
Group* Gruber,
UND
BNT162b
2 is a lipid
encoding nanopart
a icle–form
drome coro prefusion-stabi
lized, mem ulate d, nucleosid
efficaciou navirus 2 (SAR e-modifie
s S-CoV-2) brane-anchored
full-lengt severe acute d RNA vaccine
condition against coronavi
ally rus disea h spike respirato The
initial auth approved, or se 2019 protein.
BNT162b ry syn- greesauthors’ full name
orization, authorize (Covid-19 , and affilia s, acade
data beyo d for eme ) and is 2 is high tions are mic de-
MIXED COHORTS METHODS
In an ongo
trial, we ing, placebo-contr
nd 2 mon rgency use
ths after worl
on were
currently ly Appendix. Dorm
approved ed at philipDr.
unavailab of NY 10965.
.dorm
vaccinati dwide. At the time , Pfizer, 401 N. [email protected]
itzer can
etown Rd.,
listed in
be conta
the
ct-
or at
Pearl River,
randomly olled, obse le. *A list of
part icipa assigned the invest
nts 12 to 44,165 partrver-blinded, mult Clinical igator
BNT162b
2
15 years
of age to icipa nts inati onal Suppl
Trial Group s in the C4591
001
, pivotal provided
conf irme or placebo. The efficacy NEJM ementary Appeisndix, in the
.org.
receive two 16 years of age
d trial or available
at
This
vaccinati Covid-19 and safet end points were 30-µg doses, at older and 2264
on. y, which vaccine effic 21 days
were both apart, of 2021,article was published
at NEJM on Septe
RESULTS evaluated acy against labo
rator y- N .org. mber 15,
through Engl J Med
BNT162b 6 months
2 after DOI: 10.105 2021;385:176
part icipa cont inued to be 6/NEJMoa2 1-73.
nts safe Copyright
© 2021 11034
ficacy agai had adverse even and have an Massachusetts 5
acce
Pfizer took the results from their adult trial, which started July 27, 2020, and then added the results from through nst Covid-19 was ts leading to with ptable adverse-e CME
Medical
Society.
6 vent prof at NEJM
ous SAR months of follo 91.3% (95% conf drawal from the ile. .org
S-CoV-2 w-up amo trial. Vacc Few
vaccine infection ng the part idence inter val
effic who icipants [CI], 89.0 ine ef-
the 12 - 15 year olds’ trial, despite the fact that the adolescent trial started four months populatio acy. Vaccine effic could be evalu without to 93.2)
ns with acy of 86 ated. Ther evidence
Covid-19 diverse
ages to 100% e was a of previ-
amo gradual
decli
CoV-2. Vacc ng participants , sexes, race or was seen across
ethnic grou countries ne in
South Afric ine efficacy agai without evidence
nst ps, and and in
later. dominan a, where the SAR severe disease of previous infec risk factors for
t, a vacc S-CoV-2 was 96.7 tion with
ine effic % (95% SARS-
CONCLUS acy of 100% variant of conc CI, 80.3
IONS (95% CI, ern B.1.3 to 99.9)
Through 53.5 to 100) 51 (or beta) was . In
BNT162b
6 months was observed pre-
2
of follow-up
and desp .
Covid-19. had a favorable ite
(Funded safet a gradual
by BioNTech y prof ile and decline
and Pfize was in vacc
r; ClinicalT highly efficaciou ine efficacy,
rials.gov s in prev
Since it’s well known that the efficacy of the inoculations wanes over time, this gives a false boost number, enting
NCT0436
8728.)
n engl
j med 385;1
9
to the efficacy numbers. The efficacy for these two cohorts should have been reported separately, Downloade nejm.org
November
d from nejm. The New 4, 2021
org on England
Copyright November 10, 2021. Journal of Medi
© 2021
Massachus For personal use cine
etts Medi only. No 1761
cal Socie other uses
not presented as one combined result. Without this boost, their efficacy number would likely have ty. All rights
reserved.
without
permission.
fallen.
Jul 27 Dec Mar 13

Adult Trial Adolescent Data Cutoff
(16+) Trial (12 - 15) Date for
Begins Begins Efficacy
Reported in
6 Month
Study
2020 2021
JULY AUG SEP OCT NOV DEC JAN FEB MAR
32
PFIZER TRIALS DID NOT PROVE SAFETY

THEY PROVED HARM
ILLNESS DEATHS
BNT162b2 Placebo Risk Change
Efficacy BNT162b2 Placebo
(Meaning number of people diagnosed with 77 850 -91%
COVID-19.)
Related Adverse Event 20 14
(Meaning an investigator has assessed it as related 5,241 1,311 +300%
to the BNT162b2 injection.)
Any Severe Adverse Event
(Interferes significantly with normal function.)
262 150 +75%
Any Serious Adverse Event
(Involves visit to ER or hospitalization.)
127 116 +10%
These are the results of Pfizer’s own randomized control trial.
33
LEVEL 1 EVIDENCE OF HARM.
HOW THIS IS PLAYING
OUT IN THE REAL WORLD
34
ROLL OUT ACTIVE SURVEILLANCE OF PASSIVE SURVEILLANCE OF

SURVEILLANCE TRIAL PARTICIPANTS POPULATION ROLL OUT
100 100
YOU DON’T FIND WHAT Severe AE Rate AE Rate Severe AE Rate AE Rate
YOU DON’T LOOK FOR

78%
75 75
There is a dramatic difference between
71%
passive vs active monitoring of adverse
events
1. When participants were actively followed

for adverse events (AEs) in the trials, high 50 VS 50 THE SIGNAL IS LOST
percentages of adverse events were
reported.
2. Once the vaccine was rolled out at the

30%
PERCENTAGE OF TOTAL POPULATION.

population level, passive surveillance was
used with Health Canada, VAERS or the 25 25
European Yellow Card system.
When that happened, the signal was

completely lost.
5% 2% 0.29 0.07 2.5
0 0
35 N OV E M B E R 18 2 0 21 NCT04368728 v-safe NCT04368728 VAERS Health Canada UK Yellow Card
BNT162b2 Thomas Gee MMWR 2021 BNT162b2 Thomas CDC Wonder Public Access Public Access
NEJM 2021 Solicited NEJM 2021 Public Access
Solicited Unsolicited
RISING INCIDENTS OF HEART

ISSUES IN YOUNG PEOPLE
Ontario Public Health is well aware of this, as they published a report on it,
but they seem inconsistent in their concerns.
• On Sep 29, 2021, Ontario Public Health recommended young men 18-24
not take the Moderna shot, because of a 1 in 5,000 risk of
myocarditis. They suggested Pfizer shot instead, which has a 1 in
28,000 risk of myocarditis.
• But as recently as May 8, 2021, Ontario had stopped the Astra

Zeneca shot because of a 1 in 60,000 risk of clotting side effects,
which was considered too high.
•Their priorities are inconsistent.
36
THIS IS NOT NORMAL

A German news site put together a list of over 75 known
cases of athletes collapsing - and even dying - in the
last 5 months.
https://report24.news/ab-13-jahren-lange-liste-ploetzlich-verstorbener-oder-
schwerkranker-sportler/
An Israeli news site analyzed the number of sudden

deaths “on the pitch” of members of the International
Football Association (FIFA) over the past 20 years.
The average number of FIFA sudden deaths

between 2000 - 2020 was 4.2. In 2021, it was 21.
https://www.rtnews.co.il/?view=article&id=49&catid=22
THIS IS SUPPOSED TO BE RARE
https://rumble.com/vpnxkr-are-these-side-effects-extremely-rare.html
38
PFIZER’S POST MARKETING

PHARMACOVIGILANCE REPORT
• On Nov 17, 2021, the FDA released the first batch of what will ultimately be 329,000
pages they were ordered by a court to provide to satisfy a Freedom of Information
request by a group called Public Health and Medical Professionals for Transparency who
want access to the data used by the FDA to approve Pfizer’s COVID-19
inoculations. (The FDA asked in court to have over 50 years to release the documents.)
• One post marketing pharmacovigilance report submitted to the FDA, where Pfizer
tracked real world adverse events occurring in the first 2.5 months after Emergency Use
Authorization, was particularly disturbing.
✦ Over 1,200 deaths
✦ Over 25,000 nervous system adverse events
✦ Under “Safety concerns” Pfizer listed Anaphylaxis and Vaccine-Associated
Enhanced Disease
•This document should be incriminating for any agency who saw it and
called these inoculations “safe.”
39
CONSIDERABLE EVIDENCE
OF CONFLICT OF INTEREST
40
PFIZER IS
MAKING
BILLIONS
$33.5B+ in 2021 alone.
When the incentive is such an

astronomical sum of money, it only
makes sense to ensure rigorous
oversight of the process and to
ensure as many safeguards as
possible are in place.
Their agenda is their shareholders

and their bottom line, not public
health.
41
THE PUBLIC RECORD

OF PFIZER’S CORPORATE CULTURE
42 N OV E M B E R 18 2 0 21
LINKS TO THE PUBLIC RECORD

OF PFIZER’S CORPORATE CULTURE
• Pfizer Unit to Settle Charges Of Lying About Heart Valve, Jul 2, 1994 https://www.nytimes.com/1994/07/02/business/pfizer-unit-to-settle-charges-of-lying-
about-heart-valve.html
• Pfizer to Pay $430 Million Over Promoting Drug to Doctors, May 14, 2004 https://www.nytimes.com/2004/05/14/business/pfizer-to-pay-430-million-over-
promoting-drug-to-doctors.html
• $60 Million Deal In Pfizer Suit over Rezulin, July 3, 2004 https://www.nytimes.com/2004/07/03/business/60-million-deal-in-pfizer-suit.html
• Experts Conclude Pfizer Manipulated Studies, Oct 8, 2008 https://www.nytimes.com/2008/10/08/health/research/08drug.html
• Pfizer to Pay $2.3 Billion for Fraudulent Marketing, Sep 2, 2009 https://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraud-
settlement-its-history
• Pfizer Admits Paying $35 Million to Doctors Over Last 6 Months, Apr 1, 2010 https://www.news-medical.net/news/20100401/Pfizer-admits-paying-2435-
million-to-doctors-over-last-6-months.aspx
• Pfizer Pays Out to Nigerian Families of Meningitis Drug Trial Victims, Aug 12, 2011 https://www.theguardian.com/world/2011/aug/11/pfizer-nigeria-
meningitis-drug-compensation
• Pfizer Pays US$60M to Settle Allegations of Bribing Doctors, Aug 7, 2012 https://www.ctvnews.ca/health/health-headlines/pfizer-pays-us-60m-to-settle-
allegations-of-bribing-doctors-1.906216
• SEC Charges Pfizer with FCPA Violations, Aug 7, 2012 https://www.sec.gov/news/press-release/2012-2012-152htm
• US High Court Leaves Intact $142 million Verdict Against Pfizer, Dec 9, 2013 https://www.reuters.com/article/us-usa-court-pfizer-idUSBRE9B80K020131209
• Pfizer Fined Record £84.2m for Overcharging NHS, Dec 7, 2016 https://www.bbc.com/news/business-38233852
• Sonofi, FSK, Pfizer, Boehringer Must Face Zantac Class-Action Lawsuits: Court Oct 15, 2021 https://medicaldialogues.in/news/industry/pharma/sanofi-gsk-
pfizer-boehringer-must-face-zantac-class-action-lawsuits-court-83138
43
CONFLICTS OF INTEREST AMONG PFIZER REPORT AUTHORS

6 MONTH REPORT AUTHORS
Employment + Stock Employment

N. Kitchin A. Gurtman
Corresponding J. Absalon J.L. Perez
Author S. Lockhart S. Bouguermouh
R. Bailey No Conflict
P. Liberator
Last K.A. Swanson 16%
X. Xu
Author S. Roychoudhury
K. Koury
W.V. Kalina Grant/Consultant/
D. Cooper, Clinical Trial
D.B. Tresnan R.W. Frenck, Jr.
S. Mather L.L. Hammitt
P.R. Dormitzer S. Ünal
BioNTech
BioNTech U. Şahin Lead
S.J. Thomas
founders
Founderswhose W.C. Gruber Author
G. Pérez Marc
whose
stock value
stock K.U. Jansen
Conflicts
value
increased
increased
by F.P. Polack
Ö. Türeci
$9
by billion
$9B
No Conflict
84%
E.D. Moreira, Jr
H. Nell C. Zerbini
A. Schaefer Q. Yang
44
THE CDC HAS REDEFINED “VACCINE"

TO SUIT POLITICAL & PHARMACEUTICAL INTERESTS
For many years Jul 27, 2021 Aug 18, 2021 Starting Sep 2, 2021
CDC Definition of VACCINE Head of CDC Rochelle Walensky Joe Biden announced booster CDC Definition of VACCINE
went on CNN and admitted the shots for all Americans. CHANGED
"A product that stimulates a COVID-19 vaccines do not
person’s immune system to provide immunity - they don’t stop "A preparation that is used to
produce immunity to a specific people from catching or stimulate the body’s immune
disease, protecting the person transmitting COVID-19. response against diseases."
from that disease."
This looks like fraud.
45
THE MEDIA HAS BEEN CAPTURED
https://rumble.com/voz64j-brought-to-you-by-pfizer.html
46
THIS IS NO WAY
TO MANAGE A SUPPLIER
Pfizer has been indemnified for damages in case

their inoculations hurt and kill people, and Pfizer
profits to the tune of billions if the trials are
successful.
No reasonable, responsible person would have
given Pfizer carte blanche in such a situation.
Instead, you would engage in rigorous oversight
and hold them to the highest scientific
standards. This was not done.
47
THE INOCULATIONS SHOULD BE

WITHDRAWN IMMEDIATELY
• It’s clear that Pfizer - and the agencies overseeing their trials - failed to follow established,
high quality safety and efficacy protocols right from the beginning.
• We have presented Level 1 evidence of harm from Pfizer’s own trial data. Any
government which has approved these inoculations, much less mandated them, knew or
should have known from the available data that harm would be caused to
its citizens.
• Any government that approved this medical intervention for its citizens should have
ensured that the trial had used the appropriate clinical endpoints and high quality
safety science.
• Any government official who possesses this evidence and continues to

allow its citizens to be inoculated with a toxic agent is, at the very least,
negligent.
48
RECOMMENDED READING/VIEWING
PUBLISHED PAPERS REFUTING PFIZER INOCULATIONS BRITISH MEDICAL JOURNAL
• Why Are We Vaccinating Children Against COVID-19? https:// •Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s
www.sciencedirect.com/science/article/pii/S221475002100161X vaccine trial https://www.bmj.com/content/375/bmj.n2635
ONTARIO PUBLIC HEALTH EPIDEMIOLOGICAL SUMMARY

• US COVID-19 Vaccines Proven to Cause More Harm than Good Based
on Pivotal Clinical Trial Data Analyzed Using the Proper Scientific
Endpoint, “All Cause Severe Morbidity” https://www.scivisionpub.com/
• Myocarditis and Pericarditis Following Vaccination with COVID-19
mRNA Vaccines in Ontario: December 13, 2020 to September 4, 2021
pdfs/us-covid19-vaccines-proven-to-cause-more-harm-than-good-based-on-
https://www.publichealthontario.ca/-/media/documents/ncov/epi/
pivotal-clinical-trial-data-analyzed-using-the-proper-scientific--1811.pdf
covid-19-myocarditis-pericarditis-vaccines-epi.pdf?sc_lang=en
PFIZER’S NEJM PUBLISHED RESULTS
SHORT VIDEOS
• Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine https:// • Informed Consent - It’s Your Right (3 minutes) https://rumble.com/
www.nejm.org/doi/full/10.1056/nejmoa2034577
vleq43-informed-consent-its-your-right.html
• FDA Briefing Document, Dec 10, 2020 https://www.fda.gov/media/ • Brought to You by Pfizer (1 minute) https://rumble.com/voz64j-brought-
144245/download
to-you-by-pfizer.html
• Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 • Why Do We Need Vaccine Passports? (2 minutes) https://rumble.com/
Months https://www.nejm.org/doi/full/10.1056/NEJMoa2110345
vn1zof-why-do-we-need-vaccine-passports.html
• The 6 Month Supplementary Appendix https://www.nejm.org/doi/ • COVID-19 Vaccines and D-Dimer levels (9 minutes) https://rumble.com/
suppl/10.1056/NEJMoa2110345/suppl_file/
voeisj-dr-rochagn-kilian-blowing-the-whistle-on-covid-19-vaccines-and-d-
nejmoa2110345_appendix.pdf
dimer-leve.html
• How Reliable Is the PCR Test? (2 minutes) https://youtu.be/gL7Z5JmRIM4
49
WE NEED YOU
TO HOLD THEM ACCOUNTABLE
• This evidence is a tool you can use. It represents a • Share this video with friends and family. Have
real opportunity to hold our leaders accountable as group viewing sessions on Zoom and discuss it.
it is not opinion, or modelling, or real world
evidence that can be dismissed or manipulated, but • Share this video and the PDF on social media.
LEVEL 1 EVIDENCE from a randomized control When you do, please use the hashtags #CCCA
trial. As such, it has high evidentiary value. and #MoreHarmThanGood
• We’re asking that you call your MP and MPP and • Please join our mailing list at
that you ask for a 1 hour meeting. Preferably in www.canadiancovidcarealliance.org and we will
person, but Zoom will work too. update you with additional evidence as we have it.
• During the meeting, play them the video and • Follow us on social media. This linktree has all our
provide them with the PDF version. Ask them social accounts.
questions, like whether or not they were aware of
all the issues with the Pfizer trial. Or what they plan • This presentation is available in PDF and video
to do now that they are. Get them to agree to a format on our website at
follow up meeting where they will provide you with www.canadiancovidcarealliance.org
answers.
50
THE PFIZER INOCULATIONS FOR COVID-19
MORE HARM
THAN GOOD
Contact us
[email protected]
www.canadiancovidcarealliance.org

The Pfizer Inoculations Do More Harm Than Good

Uploaded by

Copyright:

Available Formats

The Pfizer Inoculations Do More Harm Than Good

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

The Pfizer Inoculations Do More Harm Than Good

Uploaded by

Copyright:

Available Formats

What are the main concerns raised about the Pfizer trials?

What are the main concerns raised about the Pfizer trials?

What evidence is presented to show the risks of the Pfizer vaccine?

What evidence is presented to show the risks of the Pfizer vaccine?

THE PFIZER INOCULATIONS FOR COVID-19

Our alliance of over 500 independent Canadian

The federal, provincial and municipal governments in Canada have a

Due diligence in research, as well as adherence to established

Deviating from those practices, causing harm and failing to

THE HIERARCHY OF EVIDENCE

• A randomized control trial is LEVEL 1

• Models are LEVEL 5 or lower as they are

•Policy should be determined by the highest

PFIZER’S ORIGINAL TRIAL REPORT

• Published in New England Journal of Medicine

ABSOLUTE RISK REDUCTION

EARLY UNBLINDING OF RANDOMIZED CONTROL TRIAL

WHAT WAS SUPPOSED TO HAPPEN WHAT ACTUALLY HAPPENED

LEVEL 1 EVIDENCE OF HARM Safety and Efficacy of the BNT162b2 mRNA

(Which means a reduction in positive cases compared to A BS T R AC T

n engl j med 385;19 nejm.org November 4, 2021 1761

A significant increase in illness, which the Pfizer

Screen capture from Pfizer 6 Month Supplementary Appendix

Related Adverse Event

Any Severe Adverse Event

Any Serious Adverse Event

Deaths after unblinding 5

Concerning Causes of Death

Total COVID-19 Related Deaths 1 2

WHAT WENT WRONG

NORMALLY, VACCINE DEVELOPMENT LOOKS LIKE THIS, WITH A TIMELINE OF 5 TO 10 YEARS.

RARELY, IT CAN BE DONE IN AS LITTLE AS 5 YEARS.

In Vitro & Human Trials Human Trials Human Trials

Animal PHASE I PHASE II PHASE III

FOR THE COVID-19 INOCULATIONS, IT WAS DONE IN 1 YEAR.

Actual Risk of Death by Age from COVID-19 Pfizer Trial Demographics

85% of the people

Yet 75+ year olds

Pfizer Trial Protocols - Exclusions

REAL WORLD PFIZER TRIAL

Experimental Group Placebo Group

LOW QUALITY SAFETY SCIENCE

NOT TESTED FOR SPREAD REDUCTION

Although vaccine passports are now being used to ostensibly prevent

This means that:

✦ Asymptomatic infection would be missed

✦ A high level of subjectivity was introduced to the

ENDPOINT DATA - Confirmed COVID Cases 8 162

FAILURE TO TEST If you add the Suspected to the

12-15 ADOLESCENT TRIAL

12 -15 ADOLESCENT TRIAL

Maddie developed gastroparesis, nausea and

In their report to the FDA, Pfizer described her

Emergency Use Authorization Amendment

Re: the 5 to 11 year old cohort

In this table, Pfizer, using predictive modelling

But even if it were true, there is no justification

There is now such a high expectation of heart

Low Level (Level 5 Evidence)

“The mortality rate is up to 20% at 6.5 years.”